Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
There will be no procedure(s) or treatment(s) carried out on patients. All data and samples
will be taken from those already stored at the investigation sites. Clinical data collected
will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system)
[TNM stage], and histopathologic description only. Strict anonymity of patient data will be
maintained.
This retrospective study is based upon the analysis of archived formalin-fixed
paraffin-embedded tissue samples and patient-related data already available at the
investigational site.
Observational
Observational Model: Cohort, Time Perspective: Retrospective
To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer.
Up to 1 year
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Belgium: Federal Agency for Medicines and Health Products, FAMHP
111294
NCT01706185
January 2008
January 2008
Name | Location |
---|